FGC
GALT icon

Financial Gravity Companies’s Galectin Therapeutics GALT Stock Holding History

Financial Gravity Companies’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$12.7K Buy
+5,997
New +$8.97K ﹤0.01% 538
2024
Q4 		$7.74K Buy
+5,997
New +$14.4K ﹤0.01% 619

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Financial Gravity Companies's GALT Position: Q2 2025 in Review

Financial Gravity Companies opened a new position in Galectin Therapeutics (GALT) in Q2 2025: 5,997 shares worth $12.7K. The stake represents ﹤0.01% of the portfolio and ranks #538 among its holdings. This is a return to the name: Financial Gravity Companies previously reported a position in GALT as recently as Q4 2024.

Financial Gravity Companies first reported a position in GALT in Q4 2024 and has held it in 2 quarters since. 86 funds tracked by Wall St. Rank hold GALT as of Q2 2025.

  • Financial Gravity Companies held 5,997 shares of Galectin Therapeutics worth $12.7K as of Q2 2025.
  • Galectin Therapeutics was a new Financial Gravity Companies position in Q2 2025.
  • Galectin Therapeutics made up ﹤0.01% of Financial Gravity Companies's portfolio in Q2 2025, its #538 holding.
  • Financial Gravity Companies first reported a position in Galectin Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • 86 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2025.

Based on Financial Gravity Companies's 13F filing for Q2 2025, filed 8 Aug 2025.